Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marco Vercellino

Showing results (41-50 of 49) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 49 results.
Journal of the Neurological Sciences|January 14, 2025
Effectiveness, safety, and impact on multiple sclerosis course of anti-CGRP monoclonal antibodiesViviana Nociti, Marina Romozzi, Pietro Annovazzi, et al.
Annals of Neurology|April 3, 2024
Determinants and Biomarkers of Progression Independent of Relapses in Multiple SclerosisMassimiliano Calabrese, Paolo Preziosa, Antonio Scalfari, et al.
Frontiers in Immunology|November 24, 2025
Prognostic value of kappa free light chain index in patients with primary progressive multiple sclerosisMartin Schmidauer, Klaus Berek, Michael Auer, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|August 15, 2024
Ocrelizumab in MS patients with persistence of disease activity after alemtuzumab: A multi-center Italian studyCaterina Lapucci, Jessica Frau, Eleonora Cocco, et al.
Multiple Sclerosis and Related Disorders|July 16, 2023
Quality of care provided by Multiple Sclerosis Centers during Covid-19 pandemic: Results of an Italian multicenter patient-centered surveyManuela Altieri, Rocco Capuano, Alvino Bisecco, et al.
The Journal of Headache and Pain|July 3, 2026
Predictive factors of response to anti-CGRP pathway drugs in people with multiple sclerosisViviana Nociti, Simone Cesarano, Marina Romozzi, et al.
Multiple Sclerosis and Related Disorders|February 20, 2026
Abuse in individuals with multiple sclerosis: the SocialMS Italian studyMarta Ponzano, Alessio Signori, Irene Schiavetti, et al.
Journal of the Neurological Sciences|May 15, 2025
Safety assessment of switching from fingolimod to siponimod: An Italian multicenter prospective studyGianmarco Abbadessa, Irene Schiavetti, Luca Bollo, et al.
CNS Drugs|January 28, 2026
Ofatumumab Versus Intravenous Ocrelizumab after Sphingosine-1-Phosphate Receptor Modulators in Patients with Relapsing-Remitting Multiple Sclerosis: A Real-World Inverse Probability of Treatment Weighting Multicenter StudyGianmarco Abbadessa, Damiano Marastoni, Floriana Bile, et al.
Pageof 5

Showing results (41-50 of 49) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 49 results.
Journal of the Neurological Sciences|January 14, 2025
Effectiveness, safety, and impact on multiple sclerosis course of anti-CGRP monoclonal antibodiesViviana Nociti, Marina Romozzi, Pietro Annovazzi, et al.
Annals of Neurology|April 3, 2024
Determinants and Biomarkers of Progression Independent of Relapses in Multiple SclerosisMassimiliano Calabrese, Paolo Preziosa, Antonio Scalfari, et al.
Frontiers in Immunology|November 24, 2025
Prognostic value of kappa free light chain index in patients with primary progressive multiple sclerosisMartin Schmidauer, Klaus Berek, Michael Auer, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|August 15, 2024
Ocrelizumab in MS patients with persistence of disease activity after alemtuzumab: A multi-center Italian studyCaterina Lapucci, Jessica Frau, Eleonora Cocco, et al.
Multiple Sclerosis and Related Disorders|July 16, 2023
Quality of care provided by Multiple Sclerosis Centers during Covid-19 pandemic: Results of an Italian multicenter patient-centered surveyManuela Altieri, Rocco Capuano, Alvino Bisecco, et al.
The Journal of Headache and Pain|July 3, 2026
Predictive factors of response to anti-CGRP pathway drugs in people with multiple sclerosisViviana Nociti, Simone Cesarano, Marina Romozzi, et al.
Multiple Sclerosis and Related Disorders|February 20, 2026
Abuse in individuals with multiple sclerosis: the SocialMS Italian studyMarta Ponzano, Alessio Signori, Irene Schiavetti, et al.
Journal of the Neurological Sciences|May 15, 2025
Safety assessment of switching from fingolimod to siponimod: An Italian multicenter prospective studyGianmarco Abbadessa, Irene Schiavetti, Luca Bollo, et al.
CNS Drugs|January 28, 2026
Ofatumumab Versus Intravenous Ocrelizumab after Sphingosine-1-Phosphate Receptor Modulators in Patients with Relapsing-Remitting Multiple Sclerosis: A Real-World Inverse Probability of Treatment Weighting Multicenter StudyGianmarco Abbadessa, Damiano Marastoni, Floriana Bile, et al.
Pageof 5